Stockholders approve reverse stock split; Nasdaq grants continued listing until Jan 12, 2024

Bone Biologics Corp

Stockholders voted 1,402,685 for, 162,168 against, 16,129 abstain to authorize reverse stock split at ratio 1:5 to 1:20.
Nasdaq Hearings Panel granted continued listing until Jan 12, 2024, subject to milestones including implementing the reverse split and meeting minimum bid price.
Company intends to implement plan to meet milestones before Jan 12 deadline; previously received delisting notice for bid price non-compliance.
Special meeting adjournment proposal was also approved but not needed since first proposal passed.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Bone Biologics Corp shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split in a range of 1-for-5 to 1-for-20 at the 2023-12-12 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2023-12-12

Exact text from the filing

The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s Common Stock in a range of 1-for-5 shares to 1-for-20 shares, at the discretion of the board of directors.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Bone Biologics Corp shareholders approved Adjournment of Special Meeting to solicit additional votes at the 2023-12-12 meeting.

Outcome: passed
Meeting: 2023-12-12

Exact text from the filing

The Company’s stockholders approved the adjournment of the Special Meeting from time to time, if necessary or appropriate, including to solicit additional votes in favor of Proposal One if there were not sufficient votes at the time of the Special Meeting to adopt Proposal One and/or to establish a quorum.

View on SEC.gov

Browse all shareholder votes →

Bone Biologics Corp filing history →

Source: SEC EDGAR

accession 0001493152-23-044661

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.